TITLE

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists

AUTHOR(S)
GARBER, ALAN J.
PUB. DATE
May 2011
SOURCE
Diabetes Care;May2011 Supplement 2, Vol. 34, pS279
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article examines the efficacy and tolerability of long-acting glucagon-like peptide 1 receptor agonists. The two classes of drugs for treating type 2 diabetes are glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors. A definition of incretin effect is presented, referring to the difference in insulin secretory response from an oral glucose load compared with intravenous glucose administration. Glucose-dependent insulinotropic polypeptide and GLP-1 are two incretin hormones used in glycemic control.
ACCESSION #
61968025

 

Related Articles

  • Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Mest, H.-J.; Mentlein, R. // Diabetologia;Apr2005, Vol. 48 Issue 4, p616 

    Inhibitors of the regulatory protease dipeptidyl peptidase-IV (DPP-IV) are currently under development in preclinical and clinical studies (several pharmaceutical companies, now in Phase III) as potential drugs for the treatment of type 2 diabetes. Their development is based on the observation...

  • Chronic Administration of Alogliptin (SYR-322), a Novel Dipeptidyl Peptidase-IV Inhibitor, Improved Beta-Cell Function in ob/ob Mice. Moritoh, Yusuke; Takeuchi, Koji; Kataoka, Osamu; Asakawa, Tomoko; Odaka, Hiroyuki // Diabetes;Jun2007 Supplement 1, Vol. 56, pA136 

    Alogliptin (SYR-322) is a novel, oral, potent, and highly selective dipeptidyl peptidase-IV (DPP-4) inhibitor under development as a once-daily treatment for type 2 diabetes (T2D). The efficacy of alogliptin was investigated in ob/ob mice, an obese model of T2D. Chronic administration of...

  • Gliptins: A New Class of Oral Antidiabetic Agents. SESHADRI, K. G.; KIRUBHA, M. H. B. // Indian Journal of Pharmaceutical Sciences;2009, Vol. 71 Issue 6, p608 

    India has the largest population of patients with type 2 diabetes mellitus. The conventional agents used to treat type 2 diabetes frequently exhibit reduced efficacy over time leading to inadequate glycaemic control and are also associated with adverse effects. Hence, there is a need for...

  • Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. Faillie, Jean-Luc; Babai, Samy; Crépin, Sabrina; Bres, Virginie; Laroche, Marie-Laure; Louet, Hervé; Petit, Pierre; Montastruc, Jean-Louis; Hillaire-Buys, Dominique // Acta Diabetologica;Jun2014, Vol. 51 Issue 3, p491 

    In the recent past, concerns have raised regarding the potential risk of acute pancreatitis among type 2 diabetic patients using incretin-based drugs such as glucagon-like peptide 1 (GLP-1) analogs and dipeptidyl peptidase 4 (DPP-4) inhibitors. The aim of this study is to investigate the...

  • COMMENTARY: Review: Incretin therapy improves glycemic control more than placebo in patients with type 2 diabetes. Vella, Adrian // ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p3 

    The author comments on the efficacy of incretin therapy for glycemic control in non-insulin-dependent diabetics. He pointed out that the glucagon-like peptide 1 (GLP1) is associated with a significant incidence of gastrointestinal adverse effects and dipeptidyl peptidase 4 (DDP4) inhibitors are...

  • Nonlinear Increase in GLP-1 Levels in Response to DPP-IV Inhibition in Healthy Adult Subjects. Dai, Haiqinq; Gustavson, Stephanie M.; Calle, Roberto A.; Hirshberg, Boaz // Diabetes;Jun2007 Supplement 1, Vol. 56, pA135 

    Dipeptidyl Peptidase IV (DPP-IV) inhibitors represent a new promising target for the treatment of T2DM. The aim of this study was to investigate the effects of DPP-IV inhibition by PF-00734200, a potent competitive DPP-IV inhibitor, on the dynamics of plasma in healthy adult subjects. In a...

  • INKRETYNY -- NOWA ÅšCIEÅ›KA DIABETOLOGII? Belowska-Bień, Kinga; Gruber, Katarzyna; Zdrojewicz, Zygmunt // Problemy Terapii Monitorowanej;dec2007, Vol. 18 Issue 4, p231 

    Two main incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) which are secreted in a nutrient-dependent manner and stimulate insulin secretion. Both GIP and GLP-1 also promote beta cell proliferation and inhibit apoptosis. GLP-1 controls glycemia...

  • Glucagon Like Peptides-1 Modulators as Newer Target for Diabetes. Vaidya, H. B.; Goyal, R. K. // Current Drug Targets;Oct2008, Vol. 9 Issue 10, p911 

    Diabetes mellitus (DM) has been recognized as a growing world-wide epidemic by many health advocacy groups including the World Health Organization (WHO). DM affects about 6% of the North American population. A recent report estimated that 8.2% of adult population worldwide has impaired glucose...

  • GLP-1 receptor agonist-induced polyarthritis: a case report. Ambrosio, Maria; Monami, Matteo; Sati, Lavinia; Marchionni, Niccolò; Bari, Mauro; Mannucci, Edoardo // Acta Diabetologica;Aug2014, Vol. 51 Issue 4, p673 

    Occasional cases of bilateral, symmetrical, seronegative polyarthritis have been reported in patients treated with dipeptidyl peptidase-4 inhibitors (Crickx et al. in Rheumatol Int, ). We report here a similar case observed during treatment with a GLP-1 receptor agonist. A 42-year-old man with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics